<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01896336</url>
  </required_header>
  <id_info>
    <org_study_id>ZPDEMS1011</org_study_id>
    <nct_id>NCT01896336</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of 5 mg Sublingual Zolpidem vs 10mg Oral Zolpidem in the Induction and Maintenance of Sleep in Patients With Primary Insomnia</brief_title>
  <official_title>National Study, Phase IV, Single-center, Double-blind, Randomized, Parallel, Controlled by 10 mg Oral Zolpidem, in Evaluating the Efficacy and Safety of Zolpidem 5 mg Sublingual in the Induction and Maintenance of Sleep in Patients With Primary Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Associação Fundo de Incentivo à Pesquisa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of sublingual zolpidem&#xD;
      presentation 5 mg in the induction of sleep in patients with primary insomnia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  National study, phase IV, single-center, double-blind, randomized, parallel, controlled&#xD;
           by zolpidem 10mg oral.&#xD;
&#xD;
        -  Experiment duration: 93 days.&#xD;
&#xD;
        -  05 visits (days -3, 0, 15, 45 and 90).&#xD;
&#xD;
        -  Efficacy will be evaluated for: Sleep induction and the maintenance of sleep.&#xD;
&#xD;
        -  Adverse events evaluation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 18, 2013</start_date>
  <completion_date type="Actual">December 10, 2013</completion_date>
  <primary_completion_date type="Actual">November 11, 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy will be measured by sleep induction and maintenance.</measure>
    <time_frame>90 days</time_frame>
    <description>Sleep induction is measured by time to sleep after administration of the investigational product.&#xD;
The maintenance will be measured by the use of medication in the middle of the night and also by the elapsed time to sleep after administration of the investigational drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be evaluated by the adverse events occurrences</measure>
    <time_frame>90 days</time_frame>
    <description>Adverse events will be collected and followed in order to evaluate safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Primary Insomnia</condition>
  <arm_group>
    <arm_group_label>5mg sublingual Zolpidem hemitartrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg oral Zolpidem hemitartrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 QD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolpidem Hemitartrate</intervention_name>
    <description>Patz - 5mg sublingual zolpidem hemitartrate&#xD;
1 QD&#xD;
Stilnox - 10mg oral zolpidem hemitartrate&#xD;
1 QD</description>
    <arm_group_label>10 mg oral Zolpidem hemitartrate</arm_group_label>
    <arm_group_label>5mg sublingual Zolpidem hemitartrate</arm_group_label>
    <other_name>Patz - 5mg sublingual zolpidem hemitartrate</other_name>
    <other_name>Stilnox - 10mg oral zolpidem hemitartrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women aged between 20 and 64 years;&#xD;
&#xD;
          -  Diagnosis of primary insomnia according to criteria defined by DSM-IV;&#xD;
&#xD;
          -  Difficulty in maintaining sleep and waking up until 3 am;&#xD;
&#xD;
          -  Not having used any psychoactive drug in the last 30 days prior to their inclusion in&#xD;
             the study;&#xD;
&#xD;
          -  Signature of IC.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous history of serious medical illness, neurological or psychiatric disorder;&#xD;
&#xD;
          -  Allergy or hypersensitivity to zolpidem;&#xD;
&#xD;
          -  Obstructive Sleep Apnea syndrome;&#xD;
&#xD;
          -  Polysomnography with apnea and hypopnea index &gt;10/hour or PLM &gt;15/h;&#xD;
&#xD;
          -  Other secondary sleep disorders;&#xD;
&#xD;
          -  History of substance abuse or dependence;&#xD;
&#xD;
          -  History of daily consumption of alcoholic beverages;&#xD;
&#xD;
          -  Pregnancy, lactation or refusal to use safe contraceptive methods during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dalva R Poyares, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associacao Fundo de Incentivo a Psicofarmcologia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AFIP</name>
      <address>
        <city>São Paulo</city>
        <state>Sâo Paulo</state>
        <zip>04020-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 8, 2013</study_first_submitted>
  <study_first_submitted_qc>July 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2013</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

